Phase III study investigating the efficacy and safety of ruxolitinib in Early Myelofibrosis patients with high molecular risk mutations

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-004928-21

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the effect of ruxolitinib in delaying progression of MF from early disease to more advanced disease stages.


Critère d'inclusion

  • Early Myelofibrosis patients with high molecular risk mutations